Safety Study of the Switch From Oral Selexipag to Intravenous Selexipag in Subjects With Stable Pulmonary Arterial Hypertension

NCT03187678 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

20

Enrollment

INDUSTRY

Sponsor class

Conditions

Pulmonary Arterial Hypertension

Interventions

DRUG: i.v. selexipag
DRUG: oral selexipag (Uptravi)

Sponsor

Actelion